Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.
Identifieur interne : 000766 ( 2020/Analysis ); précédent : 000765; suivant : 000767Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.
Auteurs : Daniel J. Drucker [Canada]Source :
- Endocrine reviews [ 1945-7189 ] ; 2020.
Abstract
Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
DOI: 10.1210/endrev/bnaa011
PubMed: 32294179
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000110
- to stream PubMed, to step Curation: 000110
- to stream PubMed, to step Checkpoint: 000606
- to stream Ncbi, to step Merge: 003A83
- to stream Ncbi, to step Curation: 003A83
- to stream Ncbi, to step Checkpoint: 003A83
- to stream Main, to step Merge: 000766
- to stream Main, to step Curation: 000766
- to stream Main, to step Exploration: 000766
- to stream 2020, to step Extraction: 000766
Links to Exploration step
pubmed:32294179Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.</title><author><name sortKey="Drucker, Daniel J" sort="Drucker, Daniel J" uniqKey="Drucker D" first="Daniel J" last="Drucker">Daniel J. Drucker</name><affiliation wicri:level="4"><nlm:affiliation>From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32294179</idno><idno type="pmid">32294179</idno><idno type="doi">10.1210/endrev/bnaa011</idno><idno type="wicri:Area/PubMed/Corpus">000110</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000110</idno><idno type="wicri:Area/PubMed/Curation">000110</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000110</idno><idno type="wicri:Area/PubMed/Checkpoint">000606</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000606</idno><idno type="wicri:Area/Ncbi/Merge">003A83</idno><idno type="wicri:Area/Ncbi/Curation">003A83</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A83</idno><idno type="wicri:Area/Main/Merge">000766</idno><idno type="wicri:Area/Main/Curation">000766</idno><idno type="wicri:Area/Main/Exploration">000766</idno><idno type="wicri:Area/2020/Extraction">000766</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.</title><author><name sortKey="Drucker, Daniel J" sort="Drucker, Daniel J" uniqKey="Drucker D" first="Daniel J" last="Drucker">Daniel J. Drucker</name><affiliation wicri:level="4"><nlm:affiliation>From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><series><title level="j">Endocrine reviews</title><idno type="eISSN">1945-7189</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Drucker, Daniel J" sort="Drucker, Daniel J" uniqKey="Drucker D" first="Daniel J" last="Drucker">Daniel J. Drucker</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000766 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000766 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= pubmed:32294179
|texte= Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32294179" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |